Aviado · Research
Longevity Daily
Wednesday, October 28, 2026
Listen
Today's Brief
German scientists rewound 60-plus years of cellular aging in human blood cells — today's must-read — raising the real possibility that biological age is a modifiable target, not a fixed destiny. A Mayo Clinic trial adds urgency to managing insulin resistance early: adults with prediabetes-range blood sugar had measurably smaller, less-connected brains, and metformin helped reverse it. NutritionFacts.org delivers a sharp evidence check showing 100% of supplement industry press releases contain deliberate "spin," making Aviado's rigorous breakdown of vitamin E's anti-inflammatory mechanism especially timely. Eli Lilly's retatrutide more than doubled Ozempic's weight loss in the first head-to-head trial — and the longevity implications are only beginning to be mapped.
10 stories2 peer-reviewed3 trials1 Aviado original
Cognitive Health & Neuroprotection
Metformin Protects Brain Structure in Adults with Insulin Resistance, 40-Week Trial Finds
A Mayo Clinic team compared brain imaging, glucose PET scans, and functional connectivity data in 74 adults aged 50–80 and found that those with prediabetes-range blood sugar and excess weight had meaningfully smaller hippocampal volumes, less white matter, lower glucose uptake, and weaker frontal-to-limbic neural connections. A 40-week placebo-controlled trial then showed metformin helped reverse several of these structural deficits. If you're managing borderline blood sugar or insulin resistance, this is a compelling case to discuss metformin's brain-protective potential with your doctor before the damage accumulates.
Read more →Yes, You Can Help Prevent Dementia — Here's the Evidence
Building on a landmark 2019 clinical trial showing intensive blood pressure control reduces mild cognitive impairment risk — a common precursor to dementia — this Psychology Today piece synthesizes the growing consensus that dementia is meaningfully preventable with proven interventions. The article outlines an accessible, actionable framework: cardiovascular management tops the list, alongside lifestyle levers with solid evidence behind them. If you have a family history of cognitive decline, this is a practical starting point, not just an encouraging headline.
Read more →Supplements & Compounds
NMN Supplementation Improves Hair Diameter, Thickness, and Texture, New Study Shows
Research highlighted by Mitsubishi Corporation Life Science shows NMN supplementation improves hair diameter, thickness, length, and texture — expanding the compound's known benefits well beyond its established role in NAD+ metabolism and cellular energy production. The findings were published in the peer-reviewed journal Cosmetics. For existing NMN users this may be a measurable cosmetic side benefit worth tracking; the core longevity and metabolic evidence base for NMN remains the stronger scientific case for supplementation.
Read more →100% of Supplement Industry Press Releases Spin the Science, Study Finds
Researchers analyzing supplement industry press releases found that every single one — 100% — contained "spin": deliberate framing strategies to hype or downplay clinical findings. Even more striking, the industry advocated for continued supplement use in over 90% of cases where studies showed no benefit or potential harm. This is a critical calibration tool for anyone making supplement decisions based on product marketing or industry-generated summaries — and a strong argument for seeking out primary research or independent analysis before spending.
Read more →Vitamin E Embeds in Your Cell Membranes to Block Inflammation at the Source
Alpha-tocopherol doesn't passively circulate in your bloodstream — it physically embeds in cell membranes at the exact sites where lipid peroxidation chain reactions begin, stopping inflammatory signaling before it can spread to the rest of the body. Multiple studies confirm it consistently lowers CRP and TNF-α, with the strongest effects in people facing elevated oxidative stress such as smokers or those with metabolic syndrome. For measurable anti-inflammatory benefit, Aviado recommends 400–800 mg/day of natural d-alpha-tocopherol taken with a fat-containing meal, with CRP testing before and after to confirm your personal response.
Read the full Aviado analysis →Research & Papers
Scientists Made an 80-Year-Old's Cells Look 19 — Is Biological Aging Actually Reversible?
In a study published in Aging Cell, German researchers took red blood cell precursors from an 80-year-old donor and reprogrammed them into neural stem cells carrying a molecular age signature resembling that of someone under 20 years old — effectively rewinding over six decades of biological aging markers in a controlled lab setting. The technique exploits cellular reprogramming to convert one cell type to another, with the striking side effect of resetting the epigenetic clock along the way. This is a lab study, not a clinical intervention, and translation to human therapies remains years away — but it is the most compelling proof yet that biological age is a malleable target, not a fixed ceiling. The researchers suggest the reprogramming process itself, not just the end state, holds clues to future rejuvenation strategies.
Read more →GLP-1 Drugs May Extend Lifespan — But Probably by Only About Two Years
At the ARDD 2026 longevity conference, researchers presented data showing proteomic aging clocks — which track biological age via plasma protein patterns — improve measurably in people taking GLP-1 drugs like Ozempic and Wegovy. The catch: early projections suggest the lifespan benefit may translate to roughly two additional years, prompting serious debate about whether GLP-1s qualify as longevity therapeutics or are primarily metabolic tools with modest longevity side effects. If you're already on a GLP-1 for metabolic reasons, this is mildly encouraging news; if you're considering one solely for lifespan extension, the evidence doesn't yet support that framing.
Read more →Lifestyle & Nutrition
He Spent Seven Figures on Longevity Tech. Four Free Habits Still Matter More.
Biologist Gary Brecka — known for using biometric modeling to predict clients' biological death dates — has personally invested heavily in longevity technology and says the interventions that move the needle most are the accessible ones: sleep quality, daily sunlight, whole-food nutrition, and consistent movement. The piece is a useful reality check for anyone tempted to spend heavily on advanced diagnostics or experimental protocols before optimizing the fundamentals. The research underpinning each of these four pillars is robust; the evidence behind many expensive longevity interventions is not.
Read more →Industry & Policy
Life Biosciences Reports First-in-Human Data for Cellular Rejuvenation Drug ER-100
Life Biosciences released interim Phase 1 data for ER-100, its cellular rejuvenation therapy for open-angle glaucoma, representing the first human evidence from a partial cellular reprogramming approach to reversing age-related disease. Interim data from three participants showed no dose-limiting toxicity — a meaningful safety milestone for a wholly novel therapeutic class — though efficacy conclusions from such a small cohort would be premature. This is a significant marker for the broader rejuvenation field: clinical-stage reprogramming data in humans is beginning to arrive.
Read more →Bye-Bye Ozempic: Eli Lilly's Retatrutide More Than Doubles Weight Loss in Head-to-Head Trial
In the first direct comparison of semaglutide (Ozempic) versus Eli Lilly's next-generation triple agonist retatrutide, the newer drug produced more than double the weight loss. If approved, retatrutide would become the most potent GLP-1-class therapy on the market — and with the longevity community actively tracking GLP-1 drugs as candidate aging interventions, a compound delivering significantly stronger cardiometabolic effects could become a meaningful longevity tool. FDA review timelines have not yet been announced.
Read more →